Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Bone Loss After Acute SCI by Zoledronic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In-patient at Rehabilitation Institute of Chicago (RIC) or an outpatient who was recently discharged from RIC~* Males and females~* Age \>/=18 years~* Medically stable in the opinion of subject's physiatrist~* SCI at within 120 days inclusive at time of screening~* SCI with inability to ambulate independently~* ASIA Impairment Scale (AIS) A, B, or C, at time of study entry~* Capable of positioning to have DXA performed~* Able to tolerate acetaminophen~* No known endocrinopathies (diabetes type 1 or 2 can be included)~* Normal TSH levels~* Normal 25-OH vitamin D levels (\>/= 20 ng/ml) at baseline (subjects may be repleted)~* Normal calcium levels~* Normal renal function (creatinine \<2.0 mg/dl)~* Well hydrated with adequate intake of liquids~* Able to return for all follow-up visits~* Capable of reading and understanding informed consent document~* Males and females of childbearing potential must be willing and able to use double barrier method of contraception for 2 months after having received study drug~Exclusion Criteria:~* Have Paget's disease of the bone~* Malignancy as a cause of acute SCI~* Have unexplained high levels of alkaline phosphatase in blood~* Any active gastrointestinal condition that results in malabsorption~* Poor dental hygiene or requirement for invasive dental procedure within two months prior to enrollment~* History of bone metastasis and skeletal malignancies~* History of alcoholism or drug abuse within the 2 years prior to study screening~* Other medical conditions that in the opinion of the investigator would preclude the subject from completing the study~* Elevated liver function tests \>2x normal~* Currently being prescribed anti-convulsants at a dose or frequency that is determined to interfere with bone metabolism as determined by the investigator~* Currently being prescribed glucocorticoids, other than inhaled glucocorticoids~* Current or recent use any bone-active agents, including any bisphosphonate, raloxifene, hormone therapy (estrogen and estrogen/progestin), calcitonin or strontium-containing compounds within 60 days of screening.~* Pregnant, planning to become pregnant, or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zol (Type: EXPERIMENTAL): Intravenous infusion of zoledronic acid (zol) 5 mg at baseline.
- Placebo (Type: EXPERIMENTAL): Intravenous infusion of placebo at baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).